Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth.

EMBO Molecular Medicine
Yuyi WangGiovanna Tosato

Abstract

The tyrosine phosphatase SHP2 is oncogenic in cancers driven by receptor-tyrosine-kinases, and SHP2 inhibition reduces tumor growth. Here, we report that SHP2 is an essential promoter of endothelial cell survival and growth in the remodeling tumor vasculature. Using genetic and chemical approaches to inhibit SHP2 activity in endothelial cells, we show that SHP2 inhibits pro-apoptotic STAT3 and stimulates proliferative ERK1/2 signaling. Systemic SHP2 inhibition in mice bearing tumor types selected for SHP2-independent tumor cell growth promotes degeneration of the tumor vasculature and blood extravasation; reduces tumor vascularity and blood perfusion; and increases tumor necrosis. Reduction of tumor growth ensues, independent of SHP2 targeting in the tumor cells, blocking immune checkpoints, or recruiting macrophages. We also show that inhibiting the Angiopoietin/TIE2/AKT cascade magnifies the vascular and anti-tumor effects of SHP2 inhibition by blocking tumor endothelial AKT signaling, not a target of SHP2. Since the SHP2 and Ang2/TIE2 pathways are active in vascular endothelial cells of human melanoma and colon carcinoma, SHP2 inhibitors alone or with Ang2/TIE2 inhibitors hold promise to effectively target the tumor endothel...Continue Reading

References

May 13, 1999·The Journal of Biological Chemistry·J H QiL Claesson-Welsh
Feb 22, 2000·The Journal of Biological Chemistry·J A UkropecM J Woolkalis
Sep 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Masahiro AokiPeter K Vogt
Dec 13, 2005·Circulation Research·Stefania MitolaFederico Bussolino
Oct 13, 2006·Proceedings of the National Academy of Sciences of the United States of America·Christopher DalyJohn S Rudge
Oct 27, 2007·Journal of Vascular Research·Hanna MannellFlorian Krotz
Feb 21, 2008·Cancer Metastasis Reviews·Gordon ChanBenjamin G Neel
Feb 24, 2009·Nature Reviews. Molecular Cell Biology·Hellmut G AugustinKari Alitalo
May 7, 2010·Nature·Suphansa SawamiphakAmparo Acker-Palmer
Feb 22, 2011·Nature Cell Biology·Peter A KreuzalerChristine J Watson
Sep 20, 2011·Cell·Michael PotentePeter Carmeliet
Jun 14, 2012·Clinical & Experimental Metastasis·Janice A Nagy, Harold F Dvorak
Sep 7, 2012·Cold Spring Harbor Perspectives in Medicine·Gavin Thurston, Christopher Daly
Mar 27, 2015·Nature Communications·Ombretta SalvucciGiovanna Tosato
Jan 23, 2016·Nature Reviews. Molecular Cell Biology·Artur Kania, Rüdiger Klein
Jun 28, 2016·Journal of Medicinal Chemistry·Jorge Garcia FortanetMatthew J LaMarche
Jul 28, 2016·Nature Reviews. Molecular Cell Biology·Michael SimonsLena Claesson-Welsh
Aug 10, 2016·Cancer Cell·Hao RanBenjamin G Neel
Nov 8, 2016·The Journal of Clinical Investigation·Hyeongil KwakGiovanna Tosato
Apr 14, 2017·Science Translational Medicine·Martina SchmittnaegelMichele De Palma
May 23, 2017·Nature Reviews. Drug Discovery·Pipsa SaharinenKari Alitalo
May 29, 2018·Nature Medicine·Sara MainardiRene Bernards
Aug 14, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jie ZhangYuehai Ke
Sep 11, 2018·The Journal of Clinical Investigation·Joy HsuMichele Ardolino
Mar 9, 2019·Cell·Rajendra S ApteNapoleone Ferrara
May 24, 2019·Journal of Controlled Release : Official Journal of the Controlled Release Society·Sarah RieckDaniela Wenzel
Jul 4, 2019·EMBO Molecular Medicine·Iris UribesalgoJosef M Penninger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.